A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

NCT06305559 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Lipidemia
Coronary Artery Disease
Plaque, Atherosclerotic

Interventions

DRUG: obicetrapib 10 mg + ezetimibe 10 mg FDC daily
OTHER: Placebo

Sponsor

NewAmsterdam Pharma